1D05 PCSK9 antagonists
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.
Merck Sharp & Dohme Corp.
C A C A C A C A A C A C C
C07K A61P C07K A61P C07K A61P C07K A61P A61K C12N A61P C07K C07K
inventional inventional additional inventional additional inventional additional inventional additional inventional inventional additional additional
Kevin Shilpa Henryk Joseph C. Holly A. Heidi Feng Pingyu Dana D. Rose M. Ayesha Yan Sonia M. Denise K. Laurence B. Jeffrey T. Peizhi (Peter) Laura Jon H.
Wang Pandit Mach Santoro Hammond Pixley Dong Zhong Wood Cubbon Sitlani Li Gregory Nawrocki Peterson Blue Luo Orsatti Condra